Business & FinanceTop StoryTop StoryLatest News
Natco Pharma Q2 results: Net profit declines 60.8% to ₹202.6 crore
Sentiment: NegativeHigh Priority
What Happened?
Natco Pharma reported a 60.8% drop in consolidated net profit to ₹202.6 crore for Q2 FY27, down from ₹517.9 crore last year. Revenue fell to ₹967.3 crore from ₹1,363 crore.
Key points
- Natco's revenue from operations decreased to ₹967.3 crore in Q2 FY27.
- Total expenses for the quarter were ₹776.2 crore, down from ₹849.3 crore a year ago.
- The company acquired an additional 13.25% stake in Adcock Ingram Holding Ltd.
- In H1 FY27, net profit fell 59% to ₹409.1 crore from ₹998.2 crore.
- An interim dividend of ₹1.25 per equity share was approved by the board.
Key insights
- The significant drop in profit may lead to increased scrutiny from investors and analysts.
- The acquisition of a stake in Adcock Ingram could impact Natco's future growth strategy.
- Continued revenue decline may prompt the company to reassess its operational strategies.
Why it matters
The decline in net profit indicates financial challenges for Natco Pharma, affecting investor confidence.
Entities
Natco Pharma· CompanyAdcock Ingram Holding Ltd.· Company
Source
Business Standard
